November 25, 2025 • 4 mins
Welcome to Ozempic Weightloss Unlocked, the show where we dive deep into the latest updates, science, and real-world impact of Ozempic and similar medications on health and lifestyle.
Ozempic, once mainly a diabetes treatment, has quickly become one of the most talked-about weight loss options worldwide, reshaping the way people approach long-term health. According to the CREO Clinic, around 12 percent of adults in the United States have now used a GLP-1 medication like Ozempic or Wegovy. The surge is so significant that it recently brought about shortages, prompting the Food and Drug Administration to permit other companies to produce compounded semaglutide medications. However, the original manufacturer, Novo Nordisk, warns that these non-branded pills are not Food and Drug Administration approved and might bring safety concerns. They have responded by filing over one hundred lawsuits against providers of these versions.
The numbers behind these medications are striking. In clinical trials, people taking semaglutide, the active ingredient in Ozempic and Wegovy, lost on average close to 15 percent of their body weight over about a year and a half. For another drug in the same class, called tirzepatide, users lost over 20 percent on average. This is a magnitude of weight loss rarely seen with previous medical approaches.
The real-world experience, though, tells a slightly different story. Outside of clinical trials, users of Ozempic typically see about a 7 to 8 percent drop in their body weight after one year. For tirzepatide, the average is closer to 12 percent. Experts say that even five percent weight loss can be enough to improve many health conditions tied to weight, including blood sugar issues and high pressure in the arteries.
The difference between clinical trials and real life may be due to a range of factors. About half of all patients stop taking these medications within the first year and four out of five end up on lower than the recommended doses. Clinical trials offer ideal support settings that are hard to maintain in everyday life, and this shapes the ultimate results.
Interestingly, Science Alert reported something new on the horizon—a daily pill in development works about as well as injectable semaglutide in helping people lose weight. In the highest dose group in early trials, people on this pill lost around 9.6 percent of their body weight. If these results hold up, it could add a convenient and more widely accessible way for people to benefit from GLP-1 based therapies.
This surge in demand is partly fueled by how quickly weight loss happens for some people. A study of users in the United Kingdom taking tirzepatide found an average loss of 15 pounds in just six weeks, or almost four pounds per week. Medical experts still urge caution, emphasizing that lasting weight loss works best with changes to eating and activity alongside any medication.
Latest research highlighted by Science Daily points to new brain targets that could lead to better GLP-1 therapies with fewer side effects, such as nausea, which remains the most common downside. Scientists hope this could someday mean drugs that deliver all the benefits of current treatments without the drawbacks, or even help address other conditions like addiction.
These medications are not just for one group—eighteen percent of Black adults in the United States report trying a GLP-1 medication, compared to ten percent of White adults and thirteen percent of Hispanic adults. The use is most common among Americans aged fifty to sixty-four, both for weight loss and for chronic disease management.
Costs remain a hot topic and can vary widely. While branded options tend to be expensive, the introduction of compounding pharmacies has altered the price landscape, though safety remains a concern.
We are watching a revolution in how people manage weight and related health concerns. New medications are being developed, ongoing research is improving our understanding, and more people than ever are engaging with these options.
Thank you for tuning in to Ozempic Weightloss Unlocked. Be sure to subscribe so you never miss the latest news in this fast-changing field. This has been a quiet please production, for more check out quiet please dot ai.
Some great Deals https://amzn.to/49SJ3Qs
For more check out http://www.quietplease.ai
This content was created in partnership and with the help of Artificial Intelligence AI
Ozempic, once mainly a diabetes treatment, has quickly become one of the most talked-about weight loss options worldwide, reshaping the way people approach long-term health. According to the CREO Clinic, around 12 percent of adults in the United States have now used a GLP-1 medication like Ozempic or Wegovy. The surge is so significant that it recently brought about shortages, prompting the Food and Drug Administration to permit other companies to produce compounded semaglutide medications. However, the original manufacturer, Novo Nordisk, warns that these non-branded pills are not Food and Drug Administration approved and might bring safety concerns. They have responded by filing over one hundred lawsuits against providers of these versions.
The numbers behind these medications are striking. In clinical trials, people taking semaglutide, the active ingredient in Ozempic and Wegovy, lost on average close to 15 percent of their body weight over about a year and a half. For another drug in the same class, called tirzepatide, users lost over 20 percent on average. This is a magnitude of weight loss rarely seen with previous medical approaches.
The real-world experience, though, tells a slightly different story. Outside of clinical trials, users of Ozempic typically see about a 7 to 8 percent drop in their body weight after one year. For tirzepatide, the average is closer to 12 percent. Experts say that even five percent weight loss can be enough to improve many health conditions tied to weight, including blood sugar issues and high pressure in the arteries.
The difference between clinical trials and real life may be due to a range of factors. About half of all patients stop taking these medications within the first year and four out of five end up on lower than the recommended doses. Clinical trials offer ideal support settings that are hard to maintain in everyday life, and this shapes the ultimate results.
Interestingly, Science Alert reported something new on the horizon—a daily pill in development works about as well as injectable semaglutide in helping people lose weight. In the highest dose group in early trials, people on this pill lost around 9.6 percent of their body weight. If these results hold up, it could add a convenient and more widely accessible way for people to benefit from GLP-1 based therapies.
This surge in demand is partly fueled by how quickly weight loss happens for some people. A study of users in the United Kingdom taking tirzepatide found an average loss of 15 pounds in just six weeks, or almost four pounds per week. Medical experts still urge caution, emphasizing that lasting weight loss works best with changes to eating and activity alongside any medication.
Latest research highlighted by Science Daily points to new brain targets that could lead to better GLP-1 therapies with fewer side effects, such as nausea, which remains the most common downside. Scientists hope this could someday mean drugs that deliver all the benefits of current treatments without the drawbacks, or even help address other conditions like addiction.
These medications are not just for one group—eighteen percent of Black adults in the United States report trying a GLP-1 medication, compared to ten percent of White adults and thirteen percent of Hispanic adults. The use is most common among Americans aged fifty to sixty-four, both for weight loss and for chronic disease management.
Costs remain a hot topic and can vary widely. While branded options tend to be expensive, the introduction of compounding pharmacies has altered the price landscape, though safety remains a concern.
We are watching a revolution in how people manage weight and related health concerns. New medications are being developed, ongoing research is improving our understanding, and more people than ever are engaging with these options.
Thank you for tuning in to Ozempic Weightloss Unlocked. Be sure to subscribe so you never miss the latest news in this fast-changing field. This has been a quiet please production, for more check out quiet please dot ai.
Some great Deals https://amzn.to/49SJ3Qs
For more check out http://www.quietplease.ai
This content was created in partnership and with the help of Artificial Intelligence AI
Mark as Played
Transcript
Episode Transcript
Available transcripts are automatically generated. Complete accuracy is not guaranteed.
Speaker 1 (00:00):
Welcome to Ozepic Weight Loss Unlocked, the show where we
dive deep into the latest updates, science and real world
impact of ozepic and similar medications on health and lifestyle. Ozepic,
once mainly a diabetes treatment, has quickly become one of
the most talked about weight loss options worldwide, reshaping the
way people approach long term health. According to the Creoclinic,
(00:23):
around twelve percent of adults in the United States have
now used a GLP one medication like ozepic or wagov.
The surge is so significant that it recently brought about shortages,
prompting the Food and Drug Administration to permit other companies
to produce compounded semaglutide medications. However, the original manufacturer, Novo Nordisk,
(00:44):
warns that these non branded pills are not Food and
Drug Administration approved and might bring safety concerns. They have
responded by filing over one hundred lawsuits against providers of
these versions. The numbers behind these medications are striking. In
clinical try people taking semiglutide, the active ingredient in Ozenpic
and wagovi, lost on average close to fifteen percent of
(01:07):
their body weight over about a year and a half.
For another drug in the same class, called tia zeppatide,
users lost over twenty percent on average. This is a
magnitude of weight loss rarely seen with previous medical approaches.
The real world experience, though, tells a slightly different story.
Outside of clinical trials, users of a zen pic typically
(01:27):
see about a seven to eight percent drop in their
body weight after one year. For tizz apathide, the average
is closer to twelve percent. Experts say that even five
percent weight loss can be enough to improve many health
conditions tied to weight, including blood sugar issues and high
pressure in the arteries. The difference between clinical trials and
real life may be due to a range of factors.
(01:49):
About half of all patients stopped taking these medications within
the first year, and four out of five end up
on lower than the recommended doses. Clinical trials offer ideal
support settings that are hard to maintain in everyday life,
and this shapes the ultimate results. Interestingly, Science Alert reported
something new on the horizon. A daily pill in development
works about as well as injectable semaglutide in helping people
(02:12):
lose weight. In the highest dose group, and early trials,
people on this pill lost around nine point six percent
of their body weight. If these results hold up, it
could add a convenient and more widely accessible way for
people to benefit from GLP one based therapies. This surgeon
demand is partly fueled by how quickly weight loss happens
for some people. A study of users in the United
Kingdom taking tizzipatid found an average loss of fifteen pounds
(02:36):
and just six weeks, or almost four pounds per week.
Medical experts still urge caution, emphasizing that lasting weight loss
works best with changes to eating and activity alongside any medication.
Latest research, highlighted by Science Daily, points to new brain
targets that could lead to better GDP one therapies with
fewer side effects such as nausea, which remains the most
(02:58):
common downside. Scientists hope this could someday mean drugs that
deliver all the benefits of current treatments without the drawbacks,
or even help address other conditions like addiction. These medications
are not just for one group. Eighteen percent of black
adults in the United States report trying a GLP one medication,
compared to ten per cent of white adults and thirteen
(03:18):
percent of Hispanic adults. The US is most common among
Americans age fifty to sixty four, both for weight loss
and for chronic disease management. Costs remain a hot topic
and can vary widely. While branded options tend to be expensive,
the introduction of compounding pharmacies has altered the price landscape,
though safety remains a concerned. We are watching a revolution
(03:39):
in how people manage weight and related health concerns. New
medications are being developed, Ongoing research is improving our understanding,
and more people than ever are engaging with these options.
Thank you for tuning in to a zenpic weight Loss Unlocked.
Be sure to subscribe so you never miss the latest
news in this fast changing field. This has been a
quiet please production. For more check out Quiet Please dot
(04:02):
a I
Welcome to Ozepic Weight Loss Unlocked, the show where we
dive deep into the latest updates, science and real world
impact of ozepic and similar medications on health and lifestyle. Ozepic,
once mainly a diabetes treatment, has quickly become one of
the most talked about weight loss options worldwide, reshaping the
way people approach long term health. According to the Creoclinic,
(00:23):
around twelve percent of adults in the United States have
now used a GLP one medication like ozepic or wagov.
The surge is so significant that it recently brought about shortages,
prompting the Food and Drug Administration to permit other companies
to produce compounded semaglutide medications. However, the original manufacturer, Novo Nordisk,
(00:44):
warns that these non branded pills are not Food and
Drug Administration approved and might bring safety concerns. They have
responded by filing over one hundred lawsuits against providers of
these versions. The numbers behind these medications are striking. In
clinical try people taking semiglutide, the active ingredient in Ozenpic
and wagovi, lost on average close to fifteen percent of
(01:07):
their body weight over about a year and a half.
For another drug in the same class, called tia zeppatide,
users lost over twenty percent on average. This is a
magnitude of weight loss rarely seen with previous medical approaches.
The real world experience, though, tells a slightly different story.
Outside of clinical trials, users of a zen pic typically
(01:27):
see about a seven to eight percent drop in their
body weight after one year. For tizz apathide, the average
is closer to twelve percent. Experts say that even five
percent weight loss can be enough to improve many health
conditions tied to weight, including blood sugar issues and high
pressure in the arteries. The difference between clinical trials and
real life may be due to a range of factors.
(01:49):
About half of all patients stopped taking these medications within
the first year, and four out of five end up
on lower than the recommended doses. Clinical trials offer ideal
support settings that are hard to maintain in everyday life,
and this shapes the ultimate results. Interestingly, Science Alert reported
something new on the horizon. A daily pill in development
works about as well as injectable semaglutide in helping people
(02:12):
lose weight. In the highest dose group, and early trials,
people on this pill lost around nine point six percent
of their body weight. If these results hold up, it
could add a convenient and more widely accessible way for
people to benefit from GLP one based therapies. This surgeon
demand is partly fueled by how quickly weight loss happens
for some people. A study of users in the United
Kingdom taking tizzipatid found an average loss of fifteen pounds
(02:36):
and just six weeks, or almost four pounds per week.
Medical experts still urge caution, emphasizing that lasting weight loss
works best with changes to eating and activity alongside any medication.
Latest research, highlighted by Science Daily, points to new brain
targets that could lead to better GDP one therapies with
fewer side effects such as nausea, which remains the most
(02:58):
common downside. Scientists hope this could someday mean drugs that
deliver all the benefits of current treatments without the drawbacks,
or even help address other conditions like addiction. These medications
are not just for one group. Eighteen percent of black
adults in the United States report trying a GLP one medication,
compared to ten per cent of white adults and thirteen
(03:18):
percent of Hispanic adults. The US is most common among
Americans age fifty to sixty four, both for weight loss
and for chronic disease management. Costs remain a hot topic
and can vary widely. While branded options tend to be expensive,
the introduction of compounding pharmacies has altered the price landscape,
though safety remains a concerned. We are watching a revolution
(03:39):
in how people manage weight and related health concerns. New
medications are being developed, Ongoing research is improving our understanding,
and more people than ever are engaging with these options.
Thank you for tuning in to a zenpic weight Loss Unlocked.
Be sure to subscribe so you never miss the latest
news in this fast changing field. This has been a
quiet please production. For more check out Quiet Please dot
(04:02):
a I
Popular Podcasts
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
Dateline NBC
Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations. Follow now to get the latest episodes of Dateline NBC completely free, or subscribe to Dateline Premium for ad-free listening and exclusive bonus content: DatelinePremium.com
Are You A Charlotte?
In 1997, actress Kristin Davis’ life was forever changed when she took on the role of Charlotte York in Sex and the City. As we watched Carrie, Samantha, Miranda and Charlotte navigate relationships in NYC, the show helped push once unacceptable conversation topics out of the shadows and altered the narrative around women and sex. We all saw ourselves in them as they searched for fulfillment in life, sex and friendships. Now, Kristin Davis wants to connect with you, the fans, and share untold stories and all the behind the scenes. Together, with Kristin and special guests, what will begin with Sex and the City will evolve into talks about themes that are still so relevant today. "Are you a Charlotte?" is much more than just rewatching this beloved show, it brings the past and the present together as we talk with heart, humor and of course some optimism.